| 产品名称 | Cediranib, Free Base | ||||||||
| 产品货号 | orb61177 | ||||||||
| 产品价格 | 现货询价，电话：010-67529703 | ||||||||
| 产品规格 | |||||||||
| 产品品牌 | Biorbyt | ||||||||
| 产品概述 | |||||||||
| 产品详情 | |||||||||
| Product Name | Cediranib | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Catalog Number | orb61177 | ||||||||
| Conjugation | Unconjugated | ||||||||
| Tested applications | HPLC, NMR | ||||||||
| Hazard Information | Non-Toxic | ||||||||
| Target | Cediranib | ||||||||
| Alternative Names | (click to expand) | ||||||||
| Storage | 2 years -20 °C as powder 2 weeks 4 °C in DMSO 6 months -80 °C in DMSO |
||||||||
| Note | For research use only. | ||||||||
| Purity | >99% pure | ||||||||
| Formula | C25H27FN4O3 | ||||||||
| MW | 450.514 g/mol | ||||||||
| CAS Number | [288383-20-0] | ||||||||
| Chemical Name | 4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline | ||||||||
| PubChem CID | CID 9933475 | ||||||||
| Application Notes | In vitro: Cediranib inhibits VEGF-stimulated proliferation with IC50 of 0.4 nM.Cediranib suppresses PDGF-AA with IC50 of 0.04 μM in MG63 cell lines.Cediranib has been shown to block Flt1-associated kinase with IC50 of 5 nM and VEGF-C and VEGF-D receptor Flt-4 with IC50 less than 3 nM.In addition, the IC50 values for inhibition of c-Kit and PDGFRβ tyrosine kinase are 2 nM and 5 nM respectively.Furthermore, no inhibition of enzyme activity is observed when 10 μM Cediranib is assayed with 100 μM ATP against AMPK, Chk1 Akt/PKB and others.Micromolar concentrations of Cediranib are needed to prevent tumor cell proliferation in vitro.
In vivo: Cediranib even suppresses tubule sprouting at subnanomolar concentrations and inhibits VEGF-induced angiogenesis.Cediranib causes hypertrophy in bone growth plate and prevents luteal development in ovary.These are physiological processes that are dependent upon angiogenesis.Cediranib shows broad spectrum activity in human tumor models at doses that are well tolerated.Besides, Cediranib causes regression of vascular tissues in human lung tumor xenografts. |
||||||||
| In vitro |
|